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Background: Research on the role of nutrition in type 2 diabetes has largely focused on macro/micronutrient
composition and dietary fiber intake, while fewer studies have tested the effects of differing food choice. Some
observational studies and short-term intervention studies suggest that a food pattern mimicking the diet with
which humans evolved positively influences glucose control and associated endocrine systems. Such a food pattern
mainly differs from other common healthy food patterns in its absence of cereal grains and dairy products. The
primary aim of this pilot study is to determine the effect of two healthy diets with or without cereal grains and
dairy products on glucose control, while keeping participants’ weight stable and other food parameters, such as
macro/micronutrient composition, dietary fiber and glycemic load, the same in both diets.
Methods/Design: We intend to include 15 adult patients with a medical diagnosis of type 2 diabetes mellitus with
or without medication and with an increased waist circumference (≥ 80 cm for women and ≥ 94 cm for men) in a
random-order cross-over diet intervention study during two periods of four-weeks separated by a six-week washout
period. Patients will be instructed to eat two healthy diets according to official dietary guidelines with respect to
macro/micronutrient composition and fiber content, but differing in the type of food included, with one diet being
without cereal grains and dairy products. Lunch will be served in a hospital kitchen for control of nutrient intake,
while the rest of the meals will be eaten at home according to specific directions. The energy content of the diets
will be individually adjusted to maintain a stable body weight during the two four-week intervention periods.
Primary outcomes will be change in fasting plasma glucagon and fructosamine, while secondary outcomes include
change in fasting glucose and glycated hemoglobin, glucose and glucagon response during oral glucose tolerance
test, blood lipids, blood pressure, C-reactive protein, body composition, quality of life, subjective experience with
the two diets, satiety scores and changes in medication.
Discussion: Using these results, we will assess the need to conduct larger and longer studies with similar design.
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The prevalence of type 2 diabetes mellitus (T2DM) has
increased dramatically (more than doubled) since 1980,
with a global prevalence of 9.8% and 9.25% for men and
women, respectively, and affecting 347 million adults in
2008 [1]. In Europe, the prevalence of T2DM is esti-
mated to be 8.1% of the adult population, affecting 52.8
million people in 2011. The estimated prevalence of
T2DM for 2030 is 9.5% of the adult population affecting
64.2 million people. T2DM accounts for 85 to 90% of all
cases of diabetes mellitus.
T2DM is one of the world’s most important causes of
mortality, disability and economic cost due to the associ-
ated increase in the risk of micro- [2] and macrovascular
[3] complications. T2DM caused 282,400 and 317,000
deaths in 2011, for men and women, respectively [4]. Es-
timates indicate that at least USD 131 million were spent
in Europe due to T2DM in 2011 [4]. In 2003, the preva-
lence of T2DM in the archipelago of Canary Islands
(Spain) was estimated to be 12% of the population with
an economic cost of €38.8 million, which accounts for
2.1% of all the health costs of the Canary Islands’ Gov-
ernment [5,6]. Furthermore, micro- and macrovascular
complications, including end-stage renal disease, are
four to five times higher than in the rest of Spain [6,7].
In impaired glucose tolerance (IGT), lifestyle interven-
tion reduces the incidence of T2DM [8], even when
compared with insulin sensitizing medication [9]. In a
study from primary health care in Stockholm, more car-
diovascular risk factors were improved after an exercise
intervention in people with normal glucose tolerance
compared with those with IGT or T2DM [10]. However,
in these studies the separate effect of exercise versus diet
could not be elucidated [11]. Data from systematic re-
views regarding the role of food in the prevention and
treatment of T2DM indicates that there are some uncer-
tainties with respect to the optimal dietary intervention
[11,12], and results from one large interventional dietary
study suggest that targeting macronutrient composition
by lowering total fat intake and increasing carbohydrate
intake from whole grains, may have detrimental effects
in women with pre-existing T2DM [13]. A recent inten-
sive diet and exercise program in patients with T2DM
was stopped because the intervention did not reduce
cardiovascular risk, despite significant weight loss at four
years, compared to the control group [14]. Research onthe role of nutrition in T2DM has largely focused on
macro/micronutrient composition and fiber intake, while
fewer studies have tested the more direct endocrine effects
of food [13,15,16]. A recent systematic review and meta-
analysis suggests that low-carbohydrate, low-glycemic
index, Mediterranean and high-protein diets may be ef-
fective in improving cardiovascular disease risk and dia-
betes management compared to control diets, with no
significant difference effect between the different interven-
tions [17]. Also, the effect of weight loss over macronutri-
ent composition precludes drawing a definitive conclusion
derived from this meta-analysis.
Theoretically, dietary interventions can improve gluca-
gon [18] and leptin physiology [19]. Thus, we speculate
that the possible effects of the diets in the ADILAN
study could be mediated, in part, by improving the ac-
tion of those hormones.
Some observational studies [20] and two short-term
intervention trials from our group [21,22] suggest that a
food pattern mimicking the diet with which humans
evolved, may be an optimal approach for patients with
T2DM. Importantly, the short-term trials compared the
experimental approach to the recommended dietary
treatment in each case, namely the Mediterranean diet
for patients with ischemic heart disease [21] and the
American Diabetes Association diet for patients with
T2DM [22], respectively. In both trials, the experimental
approach resulted in better outcomes than in the control
diet. A noteworthy finding in those dietary trials is the
significant difference in reported macronutrient compos-
ition between interventions and controls, specifically,
higher energy percentage intake for protein and fat (ex-
cept in Lindeberg et al. [21] for fat), and lower energy
percentage intake for carbohydrate in the experimental
versus the control diet, taking into account that the
intervention diet was not fixed to any dietary macronu-
trient ratio. Dietary glycemic load (GL) was also signifi-
cantly lower.
Notwithstanding these findings, the beneficial effects
shown in the experimental diets in both trials are not fully
explained by macronutrient composition or GL after fur-
ther statistical analysis [21,22]. We concluded that food
choice, rather than micro-and macronutrient composition,
may have been the most important factor leading to the
beneficial effects observed. In a recent meta-analysis com-
paring Mediterranean diets to alternative dietary strategies,
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without grains and dairy) in the study by Lindeberg et al.
[21] demonstrated the most positive effect on fasting
blood glucose of all the studies included in the meta-
analysis [23].
The Alimentation and Diabetes in Lanzarote (ADILAN) study
The major aim of the ADILAN study is to test the direct
endocrine effect of food items beyond macro/micronu-
trient composition, fiber content and glycemic load of
the diet. For this purpose, we will try to avoid weight
loss in an attempt to isolate the effect of food, as weight
loss could have been a confounding factor in the previ-
ous studies. Our objective is to run a pilot intervention
for a later long-term study with a representative sample
in patients with T2DM. The working hypothesis is that
food choice rather than macro/micronutrient composition,
fiber intake, or GL, is a major determinant for the preven-
tion and treatment of T2DM. Hypothetically, the foods
that composed the diet during most of the time of Homo
sapiens’ evolution, may be the optimal dietary approach
for the prevention and treatment of T2DM [24,25].
Methods/Design
Participants
We aim to enroll 15 participants with T2DM, males and
females, > 18 years old based, on the power calculations
(see below) estimation of a required minimum of 13 pa-
tients, allowing for one or two drop-outs. Patients live in
the island of Lanzarote, in the archipelago of Canary
Islands (Spain), located off the western coast of Africa.
Recruitment
Patients will be recruited through different strategies.
We are in collaboration with the Asociación de Diabéticos
de Lanzarote (ADILA), a local organization, whose aim is
helping patients to deal with the consequences of type 1
diabetes and T2DM. Data from 1996 estimated the preva-
lence of T2DM in Lanzarote to be 6.6% of the population
aged between 15 and 75 years old, with an absolute num-
ber of 4,067 patients [26,27]. ADILA will contact the
potential participants registered in their database by tele-
phone, Email and advertisement in the association’s bul-
letin board. In addition, we will advertise the study in the
local newspapers, radio and in some institutional websites
on the island of Lanzarote. Patients interested in partici-
pating in the study will receive general oral and/or written
information about the study. They will be informed that
our objective is to compare two healthy diets because we
do not know which, if any, is the better one. If a person is
interested, we will register their name and telephone num-
ber for further contact. After recruiting 15 potential par-
ticipants, a meeting will be arranged to provide further
details about the study.Eligibility
We will include adults (> 18 years old), males and fe-
males, with a medical diagnosis of T2DM and increased
waist circumference (≥ 80 cm for women and ≥ 94 cm
for men), with or without medication (including insulin
treatment), with stable weight for three months prior to
the start of study, who have received no change in dose
of beta blocker or thyroxine for three months prior to
the start of study, and no anticoagulant or oral steroid
treatment. Inclusion criteria are present glycated
hemoglobin (A1c) ≥ 6.0% (≥ 42.1 mmol/mol), with no
upper boundary, creatinine < 130 μmol/L and liver en-
zymes less than four times above the upper reference
value.
Procedure
The first 15 enrolled participants will undergo baseline
tests, including A1c, creatinine and liver enzymes. At
this time they will be instructed, in a group session, how
to perform the four-day weighed food record and fill the
satiety score sheets (Figure 1). Later, participants who
meet the inclusion criteria will be notified about their
final inclusion in the trial and reminded how to perform
the four-day weighed food record and satiety score. Par-
ticipants will borrow an electronic weighing scale with
tare function and will be provided with enough sheets
for the four-day weighed food record and satiety score.
Five to seven days later, they will return the food re-
cords. The baseline four-day food record will yield infor-
mation about the pre-study food choices and nutritional
composition. The four-day food record and satiety score
will be carried out at the start and end of each interven-
tion period. After receiving the first food records, partici-
pants will be appointed for the first laboratory tests and
intervention allocation. Based on total energy expenditure,
as estimated by a bio-electrical impedance analyzer model
BC-545 (Tanita Corporation, Tokyo, Japan), we will pro-
vide each participant with a menu plan with the approxi-
mate energy intake to avoid changes in body weight.
Regarding insulin titration, the participant’s physician
will handle insulin titration as needed.
Randomization
The study participants will be randomly allocated to start
with either diet A or diet B. The process will be performed
after the first laboratory testing. Randomization will be
performed by use of an Internet-based random sequence
generator from the School of Computer Science and Sta-
tistics, Trinity College, Dublin [http://www.random.org/
sequences/]. Due to the small sample size, and to avoid
unbalanced allocation of the participants to one of the
starting diets, stratified sampling by use of minimization
technique will be used. Weighting variables are starting
diet and duration of T2DM [28].
Fecha: __/__/____ Nombre: _________________________________
Lugar: Hora de comienzo a comer: :
Alimentos Crudo/cocinado
Cantidad de 





X=al inicio de la comida
O= treinta (30) minutos tras iniciar la comida
Mucha 
hambre







Figure 1 Four-day weighed food record and satiety score sheet.
Fontes-Villalba et al. Trials 2014, 15:2 Page 4 of 11
http://www.trialsjournal.com/content/15/1/2Consent
Once 15 interested persons contact the researchers, an
initial meeting with the study investigators will be ar-
ranged to give additional information about the study.
Additional eligible subjects will be placed in queue for
possible participation in case of drop-out(s). People who
are willing to participate in the study and who meet inclu-
sion criteria (medical diagnosis of T2DM, increased waist
circumference, stable body weight for three months prior
to the start of study, stable dosing of beta blockers or
thyroxine for three months prior to the start of study, and
absence of chronic oral steroid treatment, and anticoagu-
lant treatment) will receive written information about thestudy and informed consent as approved by the ethics
committee. After returning the informed consent, labora-
tory tests for plasma A1c, creatinine and liver enzymes
will be analyzed. For each person who is excluded or de-
clines participation, one person from the queue will be
contacted and informed individually.
Ethics committee and participants insurance
The ADILAN study was approved by the Ethics Committee
of Clinical Investigation (CEIC) of the Hospital Universi-
tario de Gran Canaria, Doctor Negrín (Code CEIC Negrín:
130030). The study participants will be protected against
any medical complication derived from the intervention,
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(HDI Seguros, policy number 130/002/001897), registered
at clinicaltrials.gov as NCT01891955.
Design
The ADILAN study is a randomized cross-over open
label dietary intervention trial in patients with T2DM
who will be instructed to eat two different dietary pat-
terns during two four-week periods separated by a six-
week washout period. The procedure for screening,
eligibility and recruitment is detailed in Figure 2. Sched-
ule of enrollment, interventions and assessments can be
found in Additional file 1. Detailed information about
enrollment, interventions and assessments is described
in Additional file 2.
Power calculations
The predefined primary outcomes are changes in fasting
fructosamine and glucagon. In order to detect, with 80%
power and at a significance level of 5%, a 26 μmol/L lar-
ger reduction in fructosamine after diet B than after diet
A, 12 subjects are estimated to be required. For a 37 ng/L
difference in change in fasting glucagon between the diets,
13 subjects are estimated to be required.
Intervention
The intervention is based on two diets: a) healthy diet A
(healthy diet with cereal grains and dairy products), and
b) healthy diet B (healthy diet without cereal grains and
dairy products). After randomization, there will be no
blinding to dietary assignment for study participants,
nor for those administering the interventions or asses-
sing the outcomes. Following randomization, all subjects
will receive oral and written information about their re-
spective initial dietary intervention. Owing to the fact
that all participants in both groups will start the inter-
vention at the same time, information about the specific
intervention will be provided in group sessions, one for
each group before the study starts. Prior to the begin-
ning of the second dietary period, participants will be
instructed about the new dietary intervention, in group
sessions. Each session will last one hour and will be per-
formed in the meeting room at the Hospital Insular de
Lanzarote after the laboratory tests. The degree of be-
havioral support will be the same in both interventions
in order to minimize differences in motivation. Written
information with dietary advice, a seven-day menu plan
and food recipes are similarly formulated for both diets.
The rationale behind the higher intake of whole grains,
dairy and legumes in healthy diet A is based on the pos-
sible beneficial effect of those foods in the treatment of
T2DM in some studies [29], and their prominent position
in Spanish dietary guidelines for patients with T2DM [30].
The rationale behind the exclusion of grains, dairy andlegumes in healthy diet B is based on the observed positive
effects in some previous studies [21,22].
Written information consists of a detailed seven-day
meal plan with five meals per day and corresponding rec-
ipes (Additional file 3). Participants will be requested to
follow the menu plan as much as possible when eating
away from home. They will be requested to report (in as
much detail as possible, the ingredients) any meal taken
which differs from what is stipulated in the menu plan. In
that case, they will be encouraged to photograph the meal,
and send it to one of the investigators, whenever possible.
Advice about regular physical activity will be given
equally to all subjects. Specifically, they will be recom-
mended not to change their current physical activity
during the whole trial.
One of the objectives of the study is to avoid weight
loss during the intervention. In order to accomplish this
objective, participants will be weighed once a week in
order to check for weight stability. If any participant
loses ≥ 1 kg compared to baseline, a new meeting will be
arranged for that person to adjust his/her meal plan. We
have created different versions for both menu plans in
order to provide different amounts of energy per day; spe-
cifically 1,500, 1,800, 2,000, 2,200, 2,500 and 2,800 kcal/
day. All the different menu versions maintain the same
macronutrient composition. Depending on body weight as
measured every week, each participant will be reassigned
to another (with higher or lower energy) menu plan if
their body weight changes by ≥ 1 kg. The meals will be
taken to the lunch room in two trolleys marked with
menu A or B, respectively. Each trolley will contain the
trays labeled with the participant’s name. Finally, the lunch
room will be separated in two areas for menu A and B,
respectively.
Improving patients adherence to the meal plan
Despite the notion that a healthy diet can improve glu-
cose control, adherence to dietary advice is generally
poor among patients with T2DM [31]. Moreover, the par-
ticular dietary design of this trial could increase the risk of
nonadherence. In order to minimize this risk, several
strategies will be adopted. To facilitate the participants
eating the same approximate amount of equivalent food
in every meal (expressed in grams in Additional file 3), we
will supply a table of equivalence. For example, 56 grams
of tinned tuna equates to a small tin of tuna and 20 grams
of bread corresponds to a slice of bread. Similarly, food
items such as eggs or fruits will be listed as small, medium
or large. In the case of more elaborated dishes, such as
stewed meat, baked tubers, soups, or creams, we will pro-
vide the participants with detailed recipe directions corre-
sponding to four servings, so as to facilitate the task in the
family context. On the first day of each intervention, the
investigators will review all the assigned meals, together
Figure 2 Diagram flow for Alimentation and Diabetes in Lanzarote (ADILAN).
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the directions are understandable and easy to follow. Pre-
vious to starting the study, subjects not included in the
trial will test the meals in order to elaborate a meal plan
that is understandable and easy. We will ask the partici-
pants to call one of the investigators if they have any ques-
tions regarding the meal plan. Besides this, one of the
investigators will meet the participants in the lunch room
at the beginning of each week to give behavioral support.
Furthermore, an assistant will be present on a daily basisin the lunch room to ensure that the meals are served as
planned. Also, the assistant will be asked everyday to
inquire whether the participants have any difficulties fol-
lowing the meal plans.
Healthy diet A
Healthy diet A will include fruit, vegetables, fish, shell-
fish, lean meat, nuts, eggs, olive oil and substantial
amounts of whole grains, low-fat dairy products and le-
gumes. Macronutrient composition and fiber intake will
Table 2 Daily intake of macronutrients, micronutrients,
fiber, glycemic load and index, cholesterol and water, as
calculated from seven-day menu plans
Diet P-valuea
Healthy diet A Healthy diet B
Energy
(kcal) 2,031 (142.3) 2,002 (59.5) 0.6
(MJ) 8.5 (0.6) 8.4 (0.2) 0.6
Protein
g 97.2 (7.6) 93.0 (4.2) 0.2
E% 19.0 (1.8) 18.3 (1.2) 0.4
Carbohydrates
g 245.7 (18.3) 236.7 (8.4) 0.8
E% 53.0 (3.4) 53.4 (1.5) 0.8
Fiber (g) 48.5 (10.3) 53.1 (5.7) 0.3
Glycemic load (g) 116.1 (8.0) 118.0 (11.9) 0.7
Glycemic index 47.4 (1.2) 49.8 (4.7) 0.2
Total fat (g)
g 63.6 (12.8) 62.8 (6.9) 0.89
E% 27.6 (4.6) 27.8 (2.4) 0.95
Fatty acids
Saturated (g) 13.3 (5.2) 10.9 (2.0) 0.3
Monounsaturated (g) 30.8 (5.7) 32.1 (4.2) 0.6
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to that of healthy diet B. Healthy diet A is termed
‘healthy diet with cereal grains and dairy products’. This
diet is classified as ‘very healthy’ using a Spanish vali-
dated nutritional software package [32]. It is in accordance
with official Spanish dietary recommendations for people
with T2DM regarding macronutrient composition, dietary
fiber, minerals and vitamins (Tables 1 and 2). A detailed
description of each of the meals proposed during the
course of one week is included in Additional file 3.
Healthy diet B
Healthy diet B will include fruit, vegetables, fish, shell-
fish, lean meat, nuts, eggs and olive oil. Macronutrient
composition and fiber intake will not differ from healthy
diet A. GL will also be matched to that of healthy diet
A. Healthy diet B will exclude cereal grains, legumes and
dairy products, which will largely be replaced by root
vegetables (including potatoes), vegetables, fruit and lean
meat, and slightly more fish and nuts. Healthy diet B is
termed ‘healthy diet without cereal grains and dairy
products’. Salt intake will be lower in healthy diet B.
This diet is also classified as ‘very healthy’ using vali-
dated nutritional software package [32]. It is in accord-
ance with official Spanish dietary recommendations for
people with T2DM regarding macronutrient composition,Table 1 Dietary composition of the two healthy diets
Energy content, kcal (SD) P-valuea
Healthy diet A Healthy diet B
Cereals 711.4 (105.2) 0 0.001
Legumes 185.4 (185.1) 0 0.07
Vegetables 102.6 (60.2) 421.4 (130.5) < 0.0001
Fruits 259.4 (56.1) 980.1 (183.1) 0.001
Dairy products 216.6 (53.9) 0 0.001
Meats 62.9 (62.4) 173.1 (86.6) 0.02
Fish 165.7 (90.3) 186.4 (48.5) 0.6
Eggs 49.3 (41.7) 33.2 (41.4) 0.2
Sugars and cakes 0.97 (2.6) 11.8 (28.2) 0.6
Oils and fats 245.7 (45.3) 167.1 (43.7) 0.006
Drinks 8.9 (11.5) 11.5 (6.5) 0.6
Pre-cooked food 2.2 (3.0) 3.8 (5.1) 0.6
Snacks 7.1 (18.9) 7.0 (11.5) 0.5
Sauces and dressings 12.6 (26.7) 5.6 (4.4) 0.94
Other 0.5 (1.2) 0.5 (1.2) 1.0
Total energy 2,031.3 (142.3) 2,001.7 (59.5) 0.6
Total weight 1,866.8 (300.1) 2,099.8 (184.0) 0.1
Dietary composition (kcal) of the two healthy diets, as calculated from seven-day
menu plans. Total weight in grams/day.
Values are means (SD).
aMann-Whitney U-test, except for meat, fish, oils and fats, and sauces and
dressings, total energy and total weight (t-test).
Polyunsaturated (g) 10.9 (3.0) 12.5 (2.7) 0.3
Cholesterol (mg) 257.4 (106.1) 271.4 (80.1) 0.8
Water (g) 1,395.3 (296.2) 1,708.9 (240.7) 0.05
Calcium (mg) 978.3 (123.9) 591.4 (88.6) < 0.0001
Iron (mg) 19.9 (2.8) 18.5 (2.3) 0.3
Iodine (μg) 101.7 (27.8) 143.9 (68.1) 0.15
Magnesium (mg) 570.6 (70.7) 468.6 (49.3) 0.009
Zinc (mg) 13.6 (1.8) 9.9 (2.3) 0.006
Selenium (μg) 155.7 (23.4) 126.3 (28.8) 0.057
Sodium (mg) 1,811.9 (733.9) 1,079.3 (440.7) 0.042
Potassium (mg) 3,556.0 (305.5) 6,392.9 (575.4) 0.001
Vitamin B1 (mg) 2.2 (0.3) 1.8 (0.2) 0.004
Vitamin B2 (mg) 2.2 (0.3) 1.6 (0.2) 0.001
Vitamin B3 (mg) 45.0 (5.7) 49.0 (6.9) 0.27
Vitamin B6 (mg) 2.6 (0.6) 4.2 (0.8) 0.001
Folic acid (μg) 427.6 (133.5) 506.3 (179.3) 0.37
Vitamin B12 (μg) 6.0 (1.3) 8.6 (6.3) 0.38
Vitamin C (mg) 170.1 (46.9) 434.4 (163.5) < 0.0001
Beta-carotene (μg) 4,233.7 (1494.5) 17,194.1 (6085.9) < 0.0001
Vitamin A (μg) 986.3 (582.8) 3,021.1 (1027.1) 0.001
Vitamin D (μg) 5.2 (3.6) 4.8 (3.2) 0.96
Vitamin E (mg) 13.0 (5.9) 23.7 (7.4) 0.01
Values are mean (SD).
at-test, except for carbohydrate (grams), potassium and vitamin B12
(Mann–Whitney U-test).
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tailed description of each of the meals proposed during
the course of one week is included in Additional file 3.
Dietary design
The main goal of the study is to test the hypothesis that
the type of food has an effect on glucose control, inde-
pendently of macro/micronutrient composition, fiber
content, GL and weight loss. Therefore, we generated
two different seven-day meal patterns where macro/
micronutrient composition and fiber intake are similar.
GL is also similar between both seven-day meal patterns.
Furthermore, we aim at creating two healthy food pat-
terns, according to official nutritional guidelines in
Canary Islands, utilizing a validated nutritional software
package (DIAL) [32]. The nutritional composition of the
menu plan was analyzed using another validated nutri-
tional software (Dietist XP 3.1; Kost och Näringsdata
AB, Bromma, Sweden) to check for possible errors. Min-
imal differences were observed in the results from both
programs. The distribution of macronutrient energy of
diets is 19% protein, 28% fat and 53% carbohydrate, and
18% protein, 28% fat, and 53% carbohydrate for healthy
diet A and healthy diet B, respectively. The amount of
fiber per 2,000 kcal is approximately 48.5 g and 53.1 g in
healthy diet A and healthy diet B, respectively. The GL
per 2,000 kcal is 116 and 118 in healthy diet A and
healthy diet B, respectively. Regarding micronutrient in-
take, significant differences between the two diets can be
seen in Table 2. Importantly, and because one goal of
the ADILAN trial is to avoid weight loss, dried fruits
were regularly included instead of fresh fruits, in healthy
diet B, to match the total weight of food between the
two food patterns. Two recent studies have shown that
substituting cereal grains for fruits and vegetables in-
creases satiety [19,33], and therefore it may be challen-
ging for the participants to avoid weight loss while
adhering to healthy diet B.
Evaluation
Before and after each intervention period, an oral glu-
cose tolerance test (OGTT) will be performed in the
morning after obtaining venous blood samples in the
fasting state, and measurements of blood pressure,
height (only at the start of intervention 1), weight, waist
and hip circumference, sagittal abdominal diameter, tri-
ceps, biceps, suprailiac and subscapular skinfolds, at the
start and end of both intervention periods will also be
taken. The participants will ingest 75 grams of glucose
and blood samples will be drawn for glucose and gluca-
gon at 0, 15, 30, 60, 90 and 120 minutes. Areas under
the curve (AUC) for plasma glucose (AUC glucose) and
glucagon (AUC glucagon) will be calculated. Of great
consequence, and for safety reasons, we will assesscapillary glucose, using a glucometer, before performing
the OGTT. If the result is greater than or equal to
190 mg/dL (10.5 mmol/L) the OGTT will not be per-
formed. Information about participants’ quality of life will
be assessed by means of the short form quality of life
questionnaire SF-36v2 (standard version), using the vali-
dated Spanish version, which will be filled by the partici-
pant during each of the OGTT procedures. During the
OGTT, at the end of each intervention period, patients
will also be asked to give written answers to three open-
ended questions about their experience with the dietary
pattern that they have been following during the previous
four weeks, specifically: ‘What are your thoughts about
this diet?’, ‘Describe your positive and negative experiences
with this diet’ and ‘How do you think this diet has affected
your health?’
During both dietary interventions, free lunch will be
provided every day in the kitchen of the Hospital Insular
de Lanzarote. Here, our objective is two-fold: a) to con-
trol nutrient intake as much as possible and b) to give




The primary outcomes of this study are fasting fructosa-
mine and glucagon. These outcomes will be determined
after obtaining venous blood in the fasting state at start
and end of each intervention period.
Secondary outcomes
Fasting plasma glucose, A1c, total cholesterol, LDL chol-
esterol, HDL cholesterol, triglycerides, high-sensitivity
C-reactive protein, blood pressure, and AUCs for glu-
cose and glucagon during OGTT comprise secondary
outcomes. Quality of life, assessed with the SF-36v2
questionnaire (standard version), satiety quotient (see
below), experience with the dietary patterns and change
in medication are also included as secondary outcomes.
Anthropometric measurement and laboratory tests
Trained nurses and investigators will perform the lab
tests and anthropometric measurements in the Hospital
Insular de Lanzarote. All measurements and laboratory
tests will follow standard certified methods [34].
Standing height without shoes will be measured with a
height stadiometer. Height will be reported to the near-
est 1 mm.
Weight will be measured using an electronic weighing
scale placed on a hard surface with the patient in the
fasting state. Patients will be asked to take off their
shoes, jackets, sweaters, and any other heavy clothing,
and to remove all heavy items from their pockets. Then
the patients will place both feet in the center of the
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feet. Weight is reported to the nearest 0.1 kg.
Waist circumference will be measured using a measur-
ing tape immediately above the iliac crest. Measure-
ments will be reported to the nearest 0.1 cm.
The hip circumference will be measured using a meas-
uring tape at the level of the trochanter major and re-
ported to the nearest 0.1 cm.
Sagittal abdominal diameter will be measured using a
sagittometer (that is, a sliding beam caliper with a ruler)
in the sagittal plane during a normal expiration at the
level of iliac crest (L4 to L5) with the subject in supine
position on a firm bench with the knees bent. Measure-
ments will be reported to the nearest 0.1 cm.
Blood pressure will be measured in the upper arm
(preferably right arm) at the level of the heart after five
minutes rest in the sitting position (MONICA criteria)
[34]. Ideally, the same person should perform all measure-
ments in the same patient, using the same sphygmoman-
ometer and procedure. The mean of two measurements
will be calculated as the final result.
Skinfold measurements will be taken by use of a vali-
dated caliper with a precision of 0.2 mm. The following
points will be measured as follows:
 tricipital skinfold: in the posterior part of the arm in
the middle point between the lower border of the
acromion and the vertex of the olecranon.
 bicipital skinfold: in the anterior part of the arm in
the middle point between the most external and
superior border of the acromion and the most
external and superior of the radial bone head.
 suprailiac skinfold: approximately 2.5 cm above iliac
crest in mid-axillary line.
 subscapular skinfold: in the inferior vertex of the
scapular bone.Four-day weighed food records and satiety scores
A four-day weighed food record, including one weekend
day, with weighing of each food item on an electronic
weighing scale (that could be set to zero), will be com-
pleted by the participants before the start and end of
each intervention period (Figure 1). By completing each
four-day weighed food record, participants will be asked
to rate, on a scale from 0 to 100, how well the record
represents their food habits in the preceding four weeks.
Nutrient compositions will be assessed with the nutri-
tional software package DIAL [32] used to create the
meal plans. In parallel with the four-day weighed food
records, the participants will record their subjective rat-
ing of satiety by means of a seven-point Likert-type scale
(Figure 1). Satiety Quotients will be calculated, as the
intra-meal quotient of change in satiety during meal andconsumed energy or weight of food and drink for that
specific meal.
Data management
Study data will be collected and managed using REDCap™
(Research Electronic Data Capture) electronic data cap-
ture tools hosted at Lund University [35]. REDCap™ is a
secure, web-based application designed to support data
capture for research studies, providing: 1) an intuitive
interface for validated data entry; 2) audit trails for track-
ing data manipulation and export procedures; 3) auto-
mated export procedures for seamless data downloads to
common statistical packages; and 4) procedures for
importing data from external sources.
REDCap™ will be configured according to the study
protocol in a way that the researchers can register all
data at baseline, 4, 10 and 14 weeks after study start.
Only the researchers and the hospital nurses will have
access to REDCap™. This web application allows for
management of the trial without violation of privacy or
participant confidentiality and integrity of allocation
concealment. The procedure also facilitates supervision
from abroad by some of the investigators.
Data analysis
Differences in baseline characteristics between the par-
ticipants will be measured using two-tailed unpaired t-
tests. A two-tailed paired t-test will be used to analyze
treatment effects within subjects and a two-tailed un-
paired t-test will be used to compare mean values of out-
come variables between the two diets. Normal Q-Q
plots and Shapiro-Wilk test will be performed to check
for normal distribution of data. Data transformation will
be applied in case the data does not present normal dis-
tribution. To test for a possible period effect a two-tailed
unpaired t-test comparing the mean difference between
first and second period for outcome variables and food
intake will be performed. To test a possible carry-over
effect a two-tailed unpaired t-test comparing the average
of observations for outcome variables and food intake
between the two periods will be performed. P < 0.05 will
be considered to indicate statistical significance.
Analysis will be conducted by use of SPSS for Mac
Version 20 (IBM SPSS Statistics for Mac, Version 20.0.
Armonk, NY: IBM Corp.)
Discussion
As discussed previously, there is uncertainty as to what
is the optimal dietary approach for the prevention and
treatment of T2DM [11,12,17], and previous trials from
our group raise the question of whether focusing on the
type of food, rather than macro/micronutrient compos-
ition, dietary fiber and GL is a better approach [21,22].
The ADILAN study aims at comparing the effects of
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no significant differences in macro/micronutrient com-
position, dietary fiber and GL, only different food choice.
Importantly, we will try to eliminate weight loss as a
confounding factor.
Of paramount importance, the nutritional software
package (DIAL) used to create the seven-day menu plan
generates a ‘Healthy Alimentation Index’ that classifies
both diets as ‘very healthy’. Due to its specific design,
constructed on evolutionary principles, the grain/dairy-
free diet scored zero in two items, ‘Cereals and legumes’
and ‘Dairy’, but in spite of this, it was classified as very
healthy owing to the fact that it scored the maximum
(except for ‘Variety of foods with a score of 7/10) in the
rest of items’, namely ‘Vegetables’, ‘Fruits’, ‘Meat, Fish
and Eggs’, ‘Energy derived from fat’, ‘Energy derived from
saturated fats’, ‘Cholesterol’, ‘Dietary sodium’ and ‘Variety
of foods’ [32]. It can be concluded that the ADILAN
study will compare two healthy diets which are similar
in macro/micronutrient composition, fiber intake and
GL, for the treatment of T2DM but differing in the in-
take of cereal grains, legumes and dairy products.
The ADILAN study could serve as a pilot study to run
long-term dietary intervention trials in the future, focusing
on food choice, which could shed light on a better dietary
approach for prevention and treatment of T2DM.
Trial status
The ADILAN study is currently under recruitment process
at 22 October 2013.
Additional files
Additional file 1: Schedule of enrollment, interventions, and
assessments.
Additional file 2: Detailed study diagram flow. Detailed study
diagram flow of the different events with corresponding laboratory tests
and measurements at each time point.
Additional file 3: Seven-day menu plan. Detailed daily description of
each of the proposed meals with specific weights for both diets in a
period of one week.
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